Remove 2025 Remove Dosage Remove Generic Medicine
article thumbnail

Tariffs & Trade Policy: What to Watch for, Cost Impacts, and Supply Chain Strategies

PharmTech

Generic medicines differently. Related Videos Related Content Advertisement July 24th 2025 Opposing Reactions as RFK Jr. July 23rd 2025 Overcoming PK/PD Modeling Challenges Cynthia A. Policies and levels and insurance, right? And so that really makes the market much more complex. Subscribe Now!

article thumbnail

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

PharmTech

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com Hikma Pharmaceuticals USA announced on June 28, 2025 that it is investing $1 billion by 2030 to expand its generic-drug R&D and manufacturing capabilities in its Ohio and New Jersey, United States, facilities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Moves to Strengthen Drug Supply Chain with PreCheck Program

PharmTech

Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com FDA announced on Aug. 30, 2025 that will feature a presentation of the FDA PreCheck program, stakeholder discussion, and additional considerations for overcoming onshoring challenges (2). Press Release.

FDA
article thumbnail

How much is Xigduo XR without insurance?

The Checkup by Singlecare

Without insurance, the cost of Xigduo XR varies by dosage, averaging about $390 per month, but there are ways to make it more affordable. Is there a generic for Xigduo XR? People often look for generic versions of medications to save on costs. As an extended-release tablet, it is typically taken once daily.

article thumbnail

Farxiga generic availability, cost, and dosage

The Checkup by Singlecare

Additionally, several other companies have tentative FDA approvals, meaning that their generic versions have met the requirements for FDA approval but cannot yet be marketed in the United States due to patent issues. As of January 2025, only the Prasco version of dapagliflozin is available in pharmacies.

article thumbnail

How Pharma Can Build Resilient Supply Chains Amid Trade and Tariff Shifts

PharmTech

And of course, everybody knows India is a major supplier of generic medicines to the US market. They are reportedly one of the countries that's close to reaching an agreement with the United States or some type of a deal. Subscribe Now!